Market Overview

GlycoMimetics to Report Third Quarter 2018 Financial Results on November 2, 2018


GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that it will host a
conference call and webcast to provide a corporate update and report its
third-quarter 2018 financial results on Friday, November 2, 2018, at
8:30 a.m. ET.

The dial-in number for the conference call is (844) 413-7154
(U.S. and Canada) or (216) 562-0466 (international) with passcode
9176334. To access the live audio webcast, or the subsequent archived
recording, visit the "Investors - Events & Presentations" section of the
GlycoMimetics website at
The webcast will be recorded and available for replay on the
GlycoMimetics website for 30 days following the call.

About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company focused on the
discovery and development of novel glycomimetic drugs to address unmet
medical needs resulting from diseases in which carbohydrate biology
plays a key role. GlycoMimetics' most advanced drug candidate,
rivipansel, a pan-selectin antagonist, is being developed for the
treatment of vaso-occlusive crisis in sickle cell disease and is being
evaluated in a Phase 3 clinical trial being conducted by its strategic
collaborator, Pfizer. GlycoMimetics' wholly-owned drug candidate,
GMI-1271 (uproleselan), an E-selectin antagonist, was evaluated in a
Phase 1/2 clinical trial as a potential treatment for AML and is
currently being evaluated in a Phase 1 clinical trial for the treatment
of multiple myeloma. The FDA granted uproleselan Breakthrough Therapy
designation for the treatment of adult acute myeloid leukemia (AML)
patients with relapsed/refractory disease. GlycoMimetics is also
conducting a Phase 1 clinical trial with a third drug candidate,
GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is
located in Rockville, MD in the BioHealth Capital Region. Learn more at

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements regarding the
clinical development of the company's drug candidates, including the
expected timing of completion of clinical trials and the presentation of
clinical data. Actual results may differ materially from those in these
forward-looking statements. For a further description of the risks
associated with these statements, as well as other risks facing
GlycoMimetics, please see the risk factors described in the company's
annual report on Form 10-K to be filed with the U.S. Securities and
Exchange Commission (SEC) on March 6, 2018, and other filings
GlycoMimetics makes with the SEC from time to time. Forward-looking
statements speak only as of the date of this release, and GlycoMimetics
undertakes no obligation to update or revise these statements, except as
may be required by law.

View Comments and Join the Discussion!